Yellow Card Scheme under-reporting of side effects

REVIEW ARTICLE

Lucas, Ailani et al.

Pharmacovigilance: reporting requirements throughout a product’s lifecycle

Therapeutic Advances in Drug Safety. 2022;13.

Sage Journals

DOI: https://doi.org/10.1177/20420986221125006

Reporting data confirmed variation existed in the number of e-Yellow Cards submitted annually across the six centres that provided data, suggesting there is scope for improvement. Interventions including education, persuasion, training, modelling and enablement may help address some of the barriers. A suite of interventions has been suggesting including peer discussion and support, adding Yellow Card reporting to Medical Institution team agendas, and increasing awareness of the national Standard Operating Procedures for Adverse Drug Reactions.